# Propofol
*Source: https://go.drugbank.com/drugs/DB00818*

## Overview

### Description

This compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.

### Background

Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.

### Indication

Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.

### Pharmacodynamics

Propofol is a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).

### Mechanism of Action

Gamma-aminobutyric acid receptor subunit beta-2
Potentiator
Gamma-aminobutyric acid receptor subunit beta-3
Potentiator
GABA(A) Receptor
Positive allosteric modulator

### Absorption

Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.

### Metabolism

Hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol.
Hover over products below to view reaction partners
Propofol
4-Hydroxypropofol
4-Quinol sulfate
1-Quinol glucuronide
Propofol glucuronide
1-Quinol glucuronide
4-OH-propofol

### Half-life

Initial distribution phase t
1/2α
=1.8-9.5 minutes. Second redistirubtion phase t
1/2β
=21-70 minutes. Terminal elimination phase t
1/2γ
=1.5-31 hours.

### Toxicity

Overdosage may increase pharmacologic and adverse effects or cause death.
IV LD
50
=53 mg/kg (mice), 42 mg/kg (rats). Oral LD
50
(as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Propofol is combined with 1,2-Benzodiazepine.
Abacavir
The metabolism of Abacavir can be decreased when combined with Propofol.
Abaloparatide
The risk or severity of adverse effects can be increased when Propofol is combined with Abaloparatide.
Abametapir
The serum concentration of Propofol can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Propofol can be increased when combined with Abatacept.

### Food Interactions

No interactions found.

## Chemical Information

**DrugBank ID:** DB00818

**Synonyms:** 2,6-bis(1-methylethyl)phenol
2,6-Diisopropylphenol
Propofol
Propofolum

**Chemical Formula:** C
12
H
18
O

**SMILES:** CC(C)C1=CC=CC(C(C)C)=C1O

**Weight:** Average: 178.2707
Monoisotopic: 178.135765198

**IUPAC Name:** 2,6-bis(propan-2-yl)phenol

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
CA2212794
No
2000-09-12
2015-03-17
Canada
US8476010
Yes
2013-07-02
2025-06-01
US
US5908869
Yes
1999-06-01
2015-09-22
US
US5731356
Yes
1998-03-24
2015-09-22
US
US5731355
Yes
1998-03-24
2015-09-22
US
US5714520
Yes
1998-02-03
2015-09-22
US

### Indicated Conditions

0

### Phase 0

13

### Phase 1

84

### Phase 2

121

### Phase 3

136

### Phase 4

529

### Therapeutic Categories

Anesthetics,
General

### Summary

Propofol
is a medication used in general anesthesia and for sedation.

### Brand Names

Diprivan

### Generic Name

Propofol

### DrugBank Accession Number

DB00818

### Groups

Approved, Investigational, Vet approved

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Propofol (DB00818)
×
Close

### External IDs

ICI 35-868
ICI 35,868
ICI 35868
ICI-35868
ICI35,868

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Create Account

### Associated Therapies

Induction of anesthesia therapy
Maintenance of anesthesia therapy
Monitored anesthesia care sedation
Sedative therapy

### Mechanism of action

The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.
Target
Actions
Organism
A
Gamma-aminobutyric acid receptor subunit beta-2
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit beta-3
potentiator
Humans
A
GABA(A) Receptor
positive allosteric modulator
Humans
U
Sodium channel protein type 4 subunit alpha
inhibitor
Humans
U
Sodium channel protein type 2 subunit alpha
inhibitor
Humans

### Volume of distribution

60 L/kg [healthy adults]

### Protein binding

95 to 99%, primarily to serum albumin and hemoglobin

### Route of elimination

It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.

### Clearance

23 - 50 mL/kg/min
1.6 - 3.4 L/min [70 Kg adults]

### International/Other Brands

Anepol (Ha Na Pharm)
/
Anespro (Behrens)
/
Anesvan (Chi Sheng)
/
Critifol (Abbott)
/
Disoprivan (AstraZeneca)
/
Disoprofol
/
Dormofol (Actavis)
/
Fresofol (Boryung)
/
Gobbifol (Gobbi)
/
Hipnolam (AC Farma)
/
Hypro (Celon)
/
IV-Pro (Claris Lifesciences)
/
Lipuro (B. Braun Medical)
/
Oleo-Lax (Fada)
/
Plofed (Warsaw Pharmaceutical Works)
/
Profol (Biogalenic)
/
Profolen (Blausiegel)
/
Propofabb (Hospira)
/
Propofil (Alvia)
/
Propogen (Genepharm)
/
Propolipid (Fresenius)
/
Propovan (Bharat Serums)
/
Propoven (Fresenius)
/
Provive (AFT)
/
Rapinovet
/
Recofol (Bayer)
/
Safol (Novell)
/
Trivam (Hana Pharm)
/
Troypofol (Troikaa)
/
Unifol (Claris Lifesciences)

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Diprivan
Injection, emulsion
10 mg/1mL
Intravenous
Fresenius Kabi Italia S.R.L.
2020-01-13
Not applicable
US
Diprivan
Injection, emulsion
10 mg/1mL
Intravenous
Astrazeneca Ab
1996-06-24
2010-10-31
US
Diprivan
Injection, emulsion
10 mg/1mL
Intravenous
Fresenius Kabi Italia S.R.L.
2009-11-17
Not applicable
US
Diprivan
Injection, emulsion
10 mg/1mL
Intravenous
General Injectables & Vaccines, Inc
2010-03-01
Not applicable
US
Diprivan 1%
Emulsion
10 mg / mL
Intravenous
Aspen Pharmacare Canada Inc.
1993-12-31
Not applicable
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
Amneal Pharmaceuticals LLC
2024-08-16
Not applicable
US
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
A-S Medication Solutions
2016-01-07
Not applicable
US
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
Civica, Inc.
2020-09-03
Not applicable
US
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
NorthStar Rx LLC
2022-07-01
Not applicable
US
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
Pfizer Laboratories Div Pfizer Inc
2020-10-05
Not applicable
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Anesthesia S/I-40
Propofol
(10 mg/1mL)
+
Isopropyl alcohol
(0.7 mL/1mL)
Injection, emulsion; Kit
Intravenous; Topical
RX PHARMA-PACK, INC.
2017-08-24
Not applicable
US
Anesthesia S/I-50
Propofol
(10 mg/1mL)
+
Isopropyl alcohol
(0.7 mL/1mL)
Injection, emulsion; Kit
Intravenous; Topical
RX PHARMA-PACK, INC.
2017-06-16
2018-12-14
US
Anesthesia S/I-60
Propofol
(10 mg/1mL)
+
Isopropyl alcohol
(0.7 mL/1mL)
Injection, emulsion; Kit
Intravenous; Topical
RX PHARMA-PACK, INC.
2017-06-16
Not applicable
US

### Unapproved/Other Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Fresenius Propoven 2%
Propofol
(20 mg/1mL)
Emulsion
Intravenous
Fresenius Kabi Italia S.R.L.
2020-06-05
Not applicable
US
Fresenius Propoven 2%
Propofol
(20 mg/1mL)
Emulsion
Intravenous
Fresenius Kabi Italia S.R.L.
2020-06-05
Not applicable
US
PROPOFOL % 1 FRESENIUS 10 GR 20 ML AMPUL, 5 ADET
Propofol
(1 %)
Emulsion
Intravenous
FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ.
2013-01-29
2022-11-03
Turkey
Propofol 1%
Propofol
(10 mg/1mL)
Injection, emulsion
Intravenous
Genixus
2023-03-29
Not applicable
US
Propofol Lipuro
Propofol
(10 mg/1mL)
Injection, emulsion
Intravenous
B. Braun Medical Inc.
2021-03-12
Not applicable
US

### ATC Codes

N01AX10 — Propofol
N01AX — Other general anesthetics
N01A — ANESTHETICS, GENERAL
N01 — ANESTHETICS
N — NERVOUS SYSTEM

### Drug Categories

Agents Causing Muscle Toxicity
Agents that produce hypertension
Agents that reduce seizure threshold
Anesthetics
Anesthetics, General
Anesthetics, Intravenous
Benzene Derivatives
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)
Cytochrome P-450 CYP2B6 Substrates
Cytochrome P-450 CYP2C18 Substrates
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2C8 Substrates
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP2E1 Inhibitors
Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors (weak)
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Hypnotics and Sedatives
Hypotensive Agents
Miscellaneous General Anesthetics
Nervous System
P-glycoprotein inducers
Phenols
Potential QTc-Prolonging Agents
QTc Prolonging Agents
UGT1A1 Inhibitors
UGT1A1 Substrates
UGT1A6 substrate
UGT1A9 Substrates

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Cumenes
Direct Parent
Cumenes
Alternative Parents
Phenylpropanes
/
1-hydroxy-4-unsubstituted benzenoids
/
Organooxygen compounds
/
Hydrocarbon derivatives
Substituents
1-hydroxy-4-unsubstituted benzenoid
/
Aromatic homomonocyclic compound
/
Cumene
/
Hydrocarbon derivative
/
Organic oxygen compound
/
Organooxygen compound
/
Phenol
/
Phenylpropane
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenols (
CHEBI:44915
)
/
a small molecule (
CPD-11437
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Benzene and substituted derivatives

### Sub Class

Cumenes

### Direct Parent

Cumenes

### Alternative Parents

Phenylpropanes
/
1-hydroxy-4-unsubstituted benzenoids
/
Organooxygen compounds
/
Hydrocarbon derivatives

### Substituents

1-hydroxy-4-unsubstituted benzenoid
/
Aromatic homomonocyclic compound
/
Cumene
/
Hydrocarbon derivative
/
Organic oxygen compound
/
Organooxygen compound
/
Phenol
/
Phenylpropane

### Molecular Framework

Aromatic homomonocyclic compounds

### External Descriptors

phenols (
CHEBI:44915
)
/
a small molecule (
CPD-11437
)

### Affected organisms

Humans and other mammals

### UNII

YI7VU623SF

### CAS number

2078-54-8

### InChI Key

OLBCVFGFOZPWHH-UHFFFAOYSA-N

### InChI

InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3

### Synthesis Reference

John R. Carpenter, "Propofol-based anesthetic and method of making same." U.S. Patent US6150423, issued May, 1977.
US6150423

### General References

Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. [
Article
]
Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. [
Article
]
Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Jun;25(6):460-7. doi: 10.1017/S026502150800375X. Epub 2008 Feb 26. [
Article
]
FDA Approved Drug Products: DIPRIVAN (propofol) injectable emulsion for intravenous use [
Link
]

### External Links

Human Metabolome Database
HMDB0014956
KEGG Drug
D00549
KEGG Compound
C07523
PubChem Compound
4943
PubChem Substance
46504991
ChemSpider
4774
BindingDB
50058046
RxNav
8782
ChEBI
44915
ChEMBL
CHEMBL526
ZINC
ZINC000000968303
Therapeutic Targets Database
DAP000662
PharmGKB
PA451141
PDBe Ligand
PFL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Propofol

### Human Metabolome Database

HMDB0014956

### KEGG Drug

D00549

### KEGG Compound

C07523

### PubChem Compound

4943

### PubChem Substance

46504991

### ChemSpider

4774

### BindingDB

50058046

### RxNav

8782

### ChEBI

44915

### ChEMBL

CHEMBL526

### ZINC

ZINC000000968303

### Therapeutic Targets Database

DAP000662

### PharmGKB

PA451141

### PDBe Ligand

PFL

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Propofol

### PDB Entries

1e7a
/
3p50
/
5muo
/
5mur
/
5mvm
/
5mvn
/
5mzr
/
6x3t
/
8uc7
/
9bc6

### FDA label

Download
(168 KB)

### MSDS

Download
(71.9 KB)

### Manufacturers

App pharmaceuticals llc
Bedford laboratories div ben venue laboratories inc
Hospira inc
Teva parenteral medicines inc

### Packagers

APP Pharmaceuticals
AstraZeneca Inc.
Baxter International Inc.
Cardinal Health
Hospira Inc.
Pfizer Inc.
Sicor Pharmaceuticals
Teva Pharmaceutical Industries Ltd.

### Dosage Forms

Form
Route
Strength
Injection, emulsion; kit
Intravenous; Topical
Emulsion
20.000 mg
Emulsion
Intravenous; Parenteral
10 MG/ML
Emulsion
Parenteral
1.000 g
Injection
Parenteral
200 mg/20ml
Emulsion
Intravenous
500 mg
Solution
Parenteral
20 mg
Injection
Intravenous
Emulsion
200 mg
Suspension
Intravenous
10 mg
Emulsion
Intravenous
20 mg/1mL
Emulsion
Intravenous
0.2 g
Emulsion
Parenteral
0.200 g
Injection, emulsion
Intravenous
1 %
Emulsion
20 mg/1ml
Emulsion
Intravenous
2 %
Emulsion
Parenteral
200 mg
Emulsion
Intravenous
500.00 mg
Emulsion
Intravenous
0.5 g
Injection
Parenteral
200 mg
Emulsion
Intravenous
200 mg/20ml
Emulsion
Parenteral
10 mg/1ml
Injection
Parenteral
10 mg
Injection, emulsion
Intravenous
10 mg/1mL
Injection, emulsion
Intravenous
Injection, solution
Intravenous
Emulsion
Intravenous
1 %
Emulsion
Parenteral
Emulsion
Intravenous
10 mg
Emulsion
Intravenous
1 g
Injection
Intravenous
1 %
Emulsion
Parenteral
5 MG/ML
Injection, emulsion
Parenteral
Injection, emulsion
Intravenous
1 % w/v
Injection
Intravenous
1000 mg/100ml
Injection
Intravenous
200 mg/20ml
Injection
Intravenous
500 mg/50ml
Injection, emulsion
Intravenous
10 MG/ML
Injection, emulsion
Intravenous
20 MG/ML
Emulsion
Intravenous
10 mg / mL
Emulsion
10 MG/ML
Emulsion
20 MG/ML
Emulsion
Intravenous
100 mg
Emulsion
Intravenous
200 mg
Injection, solution
Intravenous
1 %
Injection, emulsion
Intravenous
2 %
Emulsion
Intravenous
20.0 mg/ml
Emulsion
Intravenous
10 mg/ml
Emulsion
Parenteral
1 %
Injection
Intravenous
10 mg/1mL
Emulsion
10 mg
Emulsion
Parenteral
10 mg
Emulsion
Intravenous
200.00 mg
Emulsion
Intravenous
220.000 mg
Emulsion
Intravenous
10.000 mg
Injection
Parenteral
10 MG/ML
Injection
Parenteral
20 MG/ML
Injection
Intravenous
10 mg/ml
Injection
Intravenous
20 mg/ml
Emulsion
Parenteral
10 MG/ML
Emulsion
Parenteral
20 MG/ML
Injection
Intravenous
10 mg
Injection
Intravenous
1 % w/v
Emulsion
Intravenous
200.000 mg
Injection, emulsion
Parenteral
10 mg/1ml
Emulsion
10 mg/1ml
Solution
Parenteral
10 mg/1ml

### Prices

Unit description
Cost
Unit
Diprivan 10 mg/ml vial
0.93USD
ml
Propoven 1000 mg/100 ml vial
0.19USD
ml
Propoven 200 mg/20 ml ampul
0.19USD
ml
Propoven 500 mg/50 ml vial
0.19USD
ml
Propofol 10 mg/ml vial
0.13USD
ml
Propofol 1% emulsion vial
0.1USD
ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Liquid

### Experimental Properties

Property
Value
Source
melting point (°C)
18 °C
PhysProp
boiling point (°C)
256 °C
PhysProp
water solubility
124 mg/L
Not Available
logP
3.79
HANSCH,C ET AL. (1995)
pKa
11.1 (at 20 °C)
SERJEANT,EP & DEMPSEY,B (1979)

### Predicted Properties

Property
Value
Source
Water Solubility
0.158 mg/mL
ALOGPS
logP
3.81
ALOGPS
logP
4.16
Chemaxon
logS
-3
ALOGPS
pKa (Strongest Acidic)
10.98
Chemaxon
pKa (Strongest Basic)
-5
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
1
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
20.23 Å
2
Chemaxon
Rotatable Bond Count
2
Chemaxon
Refractivity
56.42 m
3
·mol
-1
Chemaxon
Polarizability
21.61 Å
3
Chemaxon
Number of Rings
1
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9955
Blood Brain Barrier
+
0.9381
Caco-2 permeable
+
0.9153
P-glycoprotein substrate
Non-substrate
0.722
P-glycoprotein inhibitor I
Non-inhibitor
0.9343
P-glycoprotein inhibitor II
Non-inhibitor
0.9883
Renal organic cation transporter
Non-inhibitor
0.9036
CYP450 2C9 substrate
Non-substrate
0.7352
CYP450 2D6 substrate
Substrate
0.7838
CYP450 3A4 substrate
Non-substrate
0.5667
CYP450 1A2 substrate
Inhibitor
0.9107
CYP450 2C9 inhibitor
Non-inhibitor
0.907
CYP450 2D6 inhibitor
Non-inhibitor
0.9368
CYP450 2C19 inhibitor
Non-inhibitor
0.9026
CYP450 3A4 inhibitor
Non-inhibitor
0.9196
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.7429
Ames test
Non AMES toxic
0.9282
Carcinogenicity
Non-carcinogens
0.7195
Biodegradation
Not ready biodegradable
0.7808
Rat acute toxicity
2.2996 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.8987
hERG inhibition (predictor II)
Non-inhibitor
0.9087
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(7.9 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-01t9-4900000000-9238ef924bbbfe181bdc
Mass Spectrum (Electron Ionization)
MS
splash10-03di-2900000000-52d81dde2dccf378a450
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00p3-5900000000-e3008f7936e6fcb4adf4
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-0900000000-04f09f9f4a3445558294
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1900000000-2c71e9f6e685d8c70f07
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-0900000000-c0e80503d12f3dfff04c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-016u-9700000000-ef93fecf64d272efa702
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014i-9500000000-a634b354ccb9caec6720
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00p3-5900000000-e3008f7936e6fcb4adf4
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-0900000000-04f09f9f4a3445558294
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1900000000-2c71e9f6e685d8c70f07
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-0900000000-c0e80503d12f3dfff04c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-016u-9700000000-ef93fecf64d272efa702
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014i-9500000000-a634b354ccb9caec6720
1H NMR Spectrum
1D NMR
Not Applicable
13C NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
149.0734608
predicted
DarkChem Lite v0.1.0
[M-H]-
138.5598058
predicted
DarkChem Lite v0.1.0
[M-H]-
148.7001608
predicted
DarkChem Lite v0.1.0
[M-H]-
144.76744
predicted
DeepCCS 1.0 (2019)
[M-H]-
149.0734608
predicted
DarkChem Lite v0.1.0
[M-H]-
138.5598058
predicted
DarkChem Lite v0.1.0
[M-H]-
148.7001608
predicted
DarkChem Lite v0.1.0
[M-H]-
144.76744
predicted
DeepCCS 1.0 (2019)
[M+H]+
148.8474608
predicted
DarkChem Lite v0.1.0
[M+H]+
144.6142271
predicted
DarkChem Lite v0.1.0
[M+H]+
149.0566608
predicted
DarkChem Lite v0.1.0
[M+H]+
147.26515
predicted
DeepCCS 1.0 (2019)
[M+H]+
148.8474608
predicted
DarkChem Lite v0.1.0
[M+H]+
144.6142271
predicted
DarkChem Lite v0.1.0
[M+H]+
149.0566608
predicted
DarkChem Lite v0.1.0
[M+H]+
147.26515
predicted
DeepCCS 1.0 (2019)
[M+Na]+
149.1342608
predicted
DarkChem Lite v0.1.0
[M+Na]+
150.9871662
predicted
DarkChem Lite v0.1.0
[M+Na]+
148.6840608
predicted
DarkChem Lite v0.1.0
[M+Na]+
155.7483
predicted
DeepCCS 1.0 (2019)
[M+Na]+
149.1342608
predicted
DarkChem Lite v0.1.0
[M+Na]+
150.9871662
predicted
DarkChem Lite v0.1.0
[M+Na]+
148.6840608
predicted
DarkChem Lite v0.1.0
[M+Na]+
155.7483
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inducer

### General Function

Translocates drugs and phospholipids across the membrane (PubMed:2897240, PubMed:35970996, PubMed:8898203, PubMed:9038218, PubMed:35507548). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:2897240, PubMed:35970996, PubMed:9038218)

### Specific Function

ABC-type xenobiotic transporter activity

### Gene Name

ABCB1

### Uniprot ID

P08183

### Uniprot Name

ATP-dependent translocase ABCB1

### Molecular Weight

141477.255 Da

### Curator comments

Current data available supporting this enzyme action are in vitro studies.

